Oral GLP-1 formulations

• US 8,785,381 B2
• Filed: 07/02/2009
• Issued: 07/22/2014
• Est. Priority Date: 12/19/2003
• Status: Active Grant

• Current Assignee: NOVO Nordisk North America Operations A/S
• Original Assignee: Emisphere Technologies, Inc. (Novo Nordisk A/S)
• Inventors: Sarubbi, Donald J.
• Primary Examiner(s): Chandra, Gyan
• Application Number:
  US12/497,373
• Publication Number:
  US 20100016229A1
• Time in Patent Office: 1,846 Days
• Field of Search: None
• US Class Current: 514/5.9
• CPC Class Codes: A61K 38/26 Glucagons

Abstract

The present invention provides pharmaceutical compositions comprising of at least one delivery agent and GLP-1. These pharmaceutical compositions facilitate the oral delivery of GLP-1, providing improved (e.g. increased) bioavailability of GLP-1 compared to administration of GLP-1 without a delivery agent.

Claims

1. A formulation comprising (i) a glucagon-like 1 peptide (GLP-1) compound having the amino acid sequence of SEQ ID NO:

2 and (ii) a delivery agent selected from the group consisting of

2. The formulation of claim 1, further comprising an excipient selected from pharmaceutically acceptable buffers, suspending agents, co-solvents, preservatives, isotonicity agents, and combinations thereof.

3. The formulation of claim 1, in the form of a tablet, capsule or particle.

4. The formulation of claim 1, wherein the GLP-1 compound is a GLP-1 analog.

5. The formulation of claim 1, wherein the GLP-1 compound is a GLP-1 derivative.

6. The formulation of claim 1, wherein the GLP-1 compound is a GLP-1 fragment.